韩宝惠-话题@MedSci

#韩宝惠#

14篇内容 | 652人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1745129, encodeId=97481e4512950, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=韩宝惠：2021年肺癌领域多项研究石破惊天，2022新药可期！, objectType=article, longId=731339, objectId=616ee313394d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=616ee313394d, replyNumber=0, likeNumber=34, createdTime=2022-11-25, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=616ee313394d, moduleTitle=韩宝惠：2021年肺癌领域多项研究石破惊天，2022新药可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=616ee313394d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745128, encodeId=30ee1e45128af, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, objectType=article, longId=300931, objectId=f500300931ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f500300931ea, replyNumber=0, likeNumber=37, createdTime=2022-09-01, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f500300931ea, moduleTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f500300931ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745127, encodeId=dd391e45127aa, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=韩宝惠：2020年肺癌靶向治疗进展年终盘点, objectType=article, longId=204261, objectId=b1c6204261db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1c6204261db, replyNumber=0, likeNumber=36, createdTime=2021-08-26, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1c6204261db, moduleTitle=韩宝惠：2020年肺癌靶向治疗进展年终盘点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1c6204261db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745125, encodeId=45771e4512509, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=韩宝惠教授：信迪利单抗联合安罗替尼一线治疗晚期NSCLC, objectType=article, longId=179297, objectId=5ed31e92972b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ed31e92972b, replyNumber=0, likeNumber=37, createdTime=2020-04-05, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ed31e92972b, moduleTitle=韩宝惠教授：信迪利单抗联合安罗替尼一线治疗晚期NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ed31e92972b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745126, encodeId=d9671e4512699, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=韩宝惠：“盘”根究底，“肺”比寻常——2019年肺癌靶向治疗年度进展盘点, objectType=article, longId=185730, objectId=b1a4185e3087, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1a4185e3087, replyNumber=0, likeNumber=32, createdTime=2020-08-15, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1a4185e3087, moduleTitle=韩宝惠：“盘”根究底，“肺”比寻常——2019年肺癌靶向治疗年度进展盘点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1a4185e3087)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745122, encodeId=3fd61e4512244, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=韩宝惠教授：IDO-抑制剂联合PD-1疗法在肺癌中的应用前景, objectType=article, longId=149754, objectId=e92c149e54ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e92c149e54ad, replyNumber=0, likeNumber=40, createdTime=2019-02-01, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e92c149e54ad, moduleTitle=韩宝惠教授：IDO-抑制剂联合PD-1疗法在肺癌中的应用前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e92c149e54ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745121, encodeId=2ab31e45121fd, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=韩宝惠教授谈如何筛选肺癌免疫治疗优势人群, objectType=article, longId=146216, objectId=77ec14621646, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77ec14621646, replyNumber=0, likeNumber=43, createdTime=2019-05-21, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77ec14621646, moduleTitle=韩宝惠教授谈如何筛选肺癌免疫治疗优势人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77ec14621646)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745124, encodeId=46501e45124db, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著, objectType=article, longId=155981, objectId=0cdf1559810c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cdf1559810c, replyNumber=0, likeNumber=34, createdTime=2019-06-14, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cdf1559810c, moduleTitle=韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cdf1559810c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745123, encodeId=1ce51e451230c, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=韩宝惠教授：EGFR突变晚期非小细胞肺癌之临床热点聚焦, objectType=article, longId=155724, objectId=2237155e2412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2237155e2412, replyNumber=0, likeNumber=25, createdTime=2019-06-30, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2237155e2412, moduleTitle=韩宝惠教授：EGFR突变晚期非小细胞肺癌之临床热点聚焦, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2237155e2412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745120, encodeId=7e4b1e45120f1, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=【WCLC 2017】韩宝惠教授解读安罗替尼更新数据：EGFR野生和突变型安罗替尼均获得双阳性结果, objectType=article, longId=116884, objectId=b99c116884cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b99c116884cd, replyNumber=0, likeNumber=39, createdTime=2017-10-23, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b99c116884cd, moduleTitle=【WCLC 2017】韩宝惠教授解读安罗替尼更新数据：EGFR野生和突变型安罗替尼均获得双阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b99c116884cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745119, encodeId=a9bb1e451197e, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=ASCO 2014：韩宝惠谈LDCT肺癌筛查的成本效益研究, objectType=article, longId=35660, objectId=0f3e3566053, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f3e3566053, replyNumber=0, likeNumber=35, createdTime=2014-07-25, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f3e3566053, moduleTitle=ASCO 2014：韩宝惠谈LDCT肺癌筛查的成本效益研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f3e3566053)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745118, encodeId=ac0f1e45118c4, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=ASCO 2014：韩宝惠谈第三代EGFR抑制剂对NSCLC的疗效, objectType=article, longId=35652, objectId=28ae35652b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ae35652b4, replyNumber=0, likeNumber=33, createdTime=2014-09-22, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ae35652b4, moduleTitle=ASCO 2014：韩宝惠谈第三代EGFR抑制剂对NSCLC的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ae35652b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745117, encodeId=84e51e451178e, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=Ann Thorac Surg：上海胸科医院韩宝惠等发现EBUS-TBNA对可疑胸内结核有很高诊断价值, objectType=article, longId=26495, objectId=3dba2649548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dba2649548, replyNumber=0, likeNumber=29, createdTime=2014-04-17, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dba2649548, moduleTitle=Ann Thorac Surg：上海胸科医院韩宝惠等发现EBUS-TBNA对可疑胸内结核有很高诊断价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dba2649548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1745116, encodeId=e4f41e4511659, content=<a href='/topic/show?id=4c99100030ab' target=_blank style='color:#2F92EE;'>#韩宝惠#</a>, objectTitle=韩宝惠：肺癌驱动基因检测指导个体化治疗, objectType=article, longId=3415, objectId=a0863415fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0863415fb, replyNumber=0, likeNumber=47, createdTime=2012-09-10, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0863415fb, moduleTitle=韩宝惠：肺癌驱动基因检测指导个体化治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0863415fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

韩宝惠

2020-05-29

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

韩宝惠：2021年肺癌领域多项研究石破惊天，2022新药可期！

2022-11-25

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当

2022-09-01

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

韩宝惠：2020年肺癌靶向治疗进展年终盘点

2021-08-26

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

韩宝惠教授：信迪利单抗联合安罗替尼一线治疗晚期NSCLC

2020-04-05

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

韩宝惠：“盘”根究底，“肺”比寻常——2019年肺癌靶向治疗年度进展盘点

2020-08-15

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

韩宝惠教授：IDO-抑制剂联合PD-1疗法在肺癌中的应用前景

2019-02-01

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

韩宝惠教授谈如何筛选肺癌免疫治疗优势人群

2019-05-21

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著

2019-06-14

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

韩宝惠教授：EGFR突变晚期非小细胞肺癌之临床热点聚焦

2019-06-30

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

【WCLC 2017】韩宝惠教授解读安罗替尼更新数据：EGFR野生和突变型安罗替尼均获得双阳性结果

2017-10-23

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

ASCO 2014：韩宝惠谈LDCT肺癌筛查的成本效益研究

2014-07-25

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

ASCO 2014：韩宝惠谈第三代EGFR抑制剂对NSCLC的疗效

2014-09-22

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

Ann Thorac Surg：上海胸科医院韩宝惠等发现EBUS-TBNA对可疑胸内结核有很高诊断价值

2014-04-17

医者仁心 (审核中...)

前往app查看评论内容

#韩宝惠#

韩宝惠：肺癌驱动基因检测指导个体化治疗

2012-09-10

科室
- - 订阅+
  - 更多科室
工具
服务